2015
DOI: 10.1016/j.jvn.2014.07.001
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacotherapy of heparin-induced thrombocytopenia: Therapeutic options and challenges in the clinical practices

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2015
2015
2018
2018

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 78 publications
(64 reference statements)
0
6
0
Order By: Relevance
“…[14] However, danaparoid is no longer available in the US and manufacturing shortages are common with this agent. [15] Direct oral anticoagulants (DOACs) such as rivaroxaban have an emerging role in the treatment of HIT and are an attractive option due to their oral administration and the limited treatment options for HIT.…”
Section: Unmet Clinical Needs For Heparin-induced Thrombocytopeniamentioning
confidence: 99%
“…[14] However, danaparoid is no longer available in the US and manufacturing shortages are common with this agent. [15] Direct oral anticoagulants (DOACs) such as rivaroxaban have an emerging role in the treatment of HIT and are an attractive option due to their oral administration and the limited treatment options for HIT.…”
Section: Unmet Clinical Needs For Heparin-induced Thrombocytopeniamentioning
confidence: 99%
“…Routine clinical and platelet monitoring is required, and patients with new/persistent platelet count reduction and/or new/extended thrombosis should be switched to an alternative anticoagulant [ 13 ]. That being said, the drug is no longer marketed in the US and has suffered manufacturing problems, causing a worldwide shortage in recent years [ 14 ].…”
Section: Current Guidelines For Hitmentioning
confidence: 99%
“…It binds highly selectively without any co-factors and can be used in patients with isolated renal impairment without dose adjustments [ 15 ]. However, its effect requires monitoring and its metabolism is strongly hepatic [ 14 ]. Dose reductions and adjustments for critically ill and cardiac surgery patients, as well as those with impaired liver function, are required for its use.…”
Section: Current Guidelines For Hitmentioning
confidence: 99%
“…LMWH are a group of anticoagulants derived from UFH by chemical or enzymatic depolymerisation methods. They consist of one third the molecular weight of UFH with a mean of 4000 to 5000 Kilo Dalton (KDa) [2,3]. Nowadays, LMWH replace UFH due to a greater inhibitory activity against factor Xa, improved pharmacokinetic properties, longer half-life, and are associated with a significant lower risk of heparin-induced thrombocytopenia [4].…”
Section: Introductionmentioning
confidence: 99%